Theragenics Corporation® is headquartered in Buford, Ga., just north of Atlanta. Theragenics® operates two business segments: brachytherapy seeds and supplies used to treat prostate cancer and surgical products. Theragenics has been a pioneer and leader in the brachytherapy market for over 30 years. The Company’s brachytherapy business manufactures, markets and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer, including the Palladium-103 TheraSeed® device and the Iodine-125 AgX100® device.
Prostate cancer is the most frequently diagnosed cancer in men and a leading cause of cancer death in men. About one in every nine men will be diagnosed with prostate cancer during his lifetime. The American Cancer Society estimates that in 2019, approximately 174,650 new cases of prostate cancer will be diagnosed in the United States alone and 31,620 men will die of the disease. Long-term clinical data has shown that brachytherapy provides a minimally invasive treatment option with results equal to or better than other treatments. Theragenics has treated more than 150,000 men for prostate cancer since 1987 when TheraSeed®, its premier palladium-103 brachytherapy device, was introduced. Today, in addition to TheraSeed®, Theragenics offers AgX100®, an I-125 brachytherapy device, as well as related brachytherapy products such as needles and spacers, and in-house loading, stranding and sterilization services.